elhamkhani
/
Test2
/
Login
Register
TriplyDB
Test2
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q28078899-0F1C41D1-DB2D-4BE0-BB9D-510FA5EC45DC
Q28078899-0F1C41D1-DB2D-4BE0-BB9D-510FA5EC45DC
BestRank
Statement
http://www.wikidata.org/entity/statement/Q28078899-0F1C41D1-DB2D-4BE0-BB9D-510FA5EC45DC
LRRK2 inhibitors and their potential in the treatment of Parkinson's disease: current perspectives
P2860
Q28078899-0F1C41D1-DB2D-4BE0-BB9D-510FA5EC45DC
BestRank
Statement
http://www.wikidata.org/entity/statement/Q28078899-0F1C41D1-DB2D-4BE0-BB9D-510FA5EC45DC
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
d13530f7e6ce5e0582c4fa9bd6b7eacd2f687526
P2860
Characterization of TAE684 as a potent LRRK2 kinase inhibitor.